Publication—A Phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

Sep 2

Ahmed Aribi, Gabriel N. Mannis, Yazan F. Madanat, et al. Blood Neoplasia. September 2025.

Oral Presentation—IO-202, A Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results